Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors.

Husam GhanimManav BatraKelly GreenJeanne HejnaSanaa AbuayshehAntione MakdissiAjay ChaudhuriParesh Dandona

Published in: Diabetes, obesity & metabolism (2021)

Dapagliflozin administration in T2D resulted in both acute and chronic reduction in systolic BP, a reduction in vasoconstrictors and an increase in vasodilators. These changes may potentially contribute to its antihypertensive effects and its benefits in congestive cardiac failure.

Keyphrases

blood pressure
hypertensive patients
left ventricular
heart rate
liver failure
drug induced
respiratory failure
blood glucose
metabolic syndrome
hepatitis b virus
acute respiratory distress syndrome